Wall Street Said It Couldn't Be Done, We Did It Anyway with Wayne Paterson

Wayne Paterson, CEO and Vice Chairman of Anteris Technologies, joins host Jordan Bergen for a frank conversation about pivoting a failing drug company into the structural heart space and building what may be medtech's next billion-dollar product.Wayne shares how 36 drug launches, a pharma-first lens on total disease management, and a blank sheet of paper led to the world's first biomimetic transcatheter heart valve — and why the market's two dominant players never saw it coming.Key TopicsHow a 25-year pharma career became the unlikely blueprint for disrupting TAVRBuilding the first biomimetic TAVR valve from blank sheet to 140 patientsRaising capital from scrappy warrants to a record-breaking $320M oversubscribed roundRunning the first randomised head-to-head RCT against Edwards and MedtronicWhy valve-in-valve is the next $3 billion opportunity and how DurAVR is already leading itRelated InsightsWhy total disease management thinking standard in pharma is largely absent from structural heartHow Medtronic ended up on Anteris's register, and why values drove the partner selectionWhat lifecycle management from oncology can teach the medtech industry about long-term product strategyThe difference between engineering a device and treating a disease and why it matters for patient outcomes Core ChallengesExisting TAVR valves leave patients in mild disease (20mmHg mean gradient). DurAVR targets the pre-disease state at 5–10mmHg a clinically meaningful and commercially critical distinction.Getting 140 patients to consistent, curative outcomes without a prior blueprint required breaking conventional medtech development norms and keeping lead physicians in the room throughout.Attracting institutional-grade talent to an early-stage, non-revenue public company meant years of patient execution before the brand had the equity to compete with Medtronic and Edwards for top-tier hires. Tune in now to hear how Wayne Paterson took a failing ASX-listed drug company, bet everything on a radically new valve design, and built what could be medtech's most important structural heart product in a decade.